The global blood cancer therapeutics market is projected to expand from $70.8 billion in 2024 to $125.5 billion by 2030, representing a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030, according to BCC Research's report Blood Cancer Therapeutics: Global Markets to 2030. Growth is being driven by rising blood cancer incidence associated with obesity, poor diet and smoking, alongside increased adoption of precision medicine (treatments tailored to genetic and molecular profiles), stronger research and development spending, and a broad pipeline of novel therapies. North America accounts for 52.4% of global revenue, supported by reimbursement conditions, established oncology infrastructure and adoption of CAR T-cell therapies (immune cells modified to attack cancer) and bispecific antibodies. The top 50 pharmaceutical companies increased R&D spending by nearly 60% between 2012 and 2022, reaching approximately $167 billion in 2022. Emerging treatments include CAR T-cell therapies such as Breyanzi and Abecma, BiTE antibodies such as BLINCYTO, antibody-drug conjugates including Trodelvy, POLIVY and ADCETRIS, second-generation BTK inhibitors such as Calquence, and first-in-class protein degraders targeting AML. Investment risks include biosimilar competition, European HTA reimbursement complexity, scrutiny of accelerated approvals and access gaps in GCC and developing markets.